JavaScript 似乎在您的浏览器中被禁用。 为了您在我们网站能获得最好的体验，建议在浏览器中打开Javascript。

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

跳转到图像库的开头

EasySep™人CD45去除试剂盒II

免疫磁珠法去除人CD45+细胞

只有 %1 左

率先评论此产品

¥8,708.00

产品号 #（选择产品）

产品号 #17898_C

免疫磁珠法去除人CD45+细胞

产品优势

快捷、操作简单，且无需分离柱
CD45+细胞的去除效率高达4 log
分选得到的细胞不带标记

产品组分包括

EasySep™人CD45去除试剂盒II（产品号 #17898）

EasySep™人CD45去除抗体混合物II，1mL
EasySep™ Dextran RapidSpheres™ 磁珠，2x1mL

RoboSep™人CD45去除试剂盒II（产品号 #17898RF）

EasySep™人CD45去除抗体混合物II，1mL
EasySep™ Dextran RapidSpheres™ 磁珠，2x1mL
RoboSep™ 缓冲液（产品号 #20104）
RoboSep™过滤吸头（产品号 #20125）

立即询价

要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。

EasySep™磁极
EasySep™缓冲液

总览

实验数据

产品说明书及文档

总览

使用EasySep™人CD45去除试剂盒II，可通过免疫磁珠选择高效去除新鲜或冻存人外周血单个核细胞(PBMC)样本中的CD45+细胞。EasySep™技术结合单克隆抗体的特异性和免分离柱系统的简便性，已在发表的研究中广泛应用超过20年。

此简单优化的EasySep™流程包含用可以识别CD45的抗体复合物和磁珠标记细胞，之后标记的细胞通过EasySep™磁铁分离，最后只需通过简单倾倒去除未标记细胞即可。CD45细胞保留在管中。分选后的细胞可立即用于下游应用，例如流式细胞术、培养或DNA/RNA 提取。CD45抗原在除红细胞和血小板外的所有血源细胞上表达。

该产品可替代EasySep™人CD45去除试剂盒 (产品号 #18259) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。探索更多产品优化您的实验流程优化，包括培养基、添加剂、抗体等。

磁极兼容性
• EasySep™磁极（产品号 #18000）
• “The Big Easy” EasySep™磁极（产品号 #18001）
• RoboSep™-S（产品号 #21000）

分类
细胞分选试剂盒

细胞类型
癌细胞及细胞系

种属
人

样本来源
PBMC

分选方法
去除

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
癌症，药物发现和毒性检测，免疫学，干细胞生物学

查看更多显示更少

实验数据

Figure 1. Typical EasySep™ Human CD45 Depletion Profile

In the example above, CAMA cells were seeded into PBMCs at a starting frequency of 1.1% (98.9% CD45+; gated on DRAQ5™ for nucleated cells). The CAMA cell (EpCAM+) content of the depleted fraction is 98%, which is a 4.0 log depletion of CD45+ cells.
NOTE: EpCAM is an antibody against an epithelial cell surface antigen expressed on CAMA cells.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

产品说明书

Product Name

RoboSep™ 人CD45去除试剂盒II

Catalog #

17898RF

Lot #

All

Language

中文

Document Type

产品说明书

Product Name

EasySep™人CD45去除试剂盒II

Catalog #

17898

Lot #

All

Language

中文

Document Type

Product Information Sheet

Product Name

RoboSep™ Human CD45 Depletion Kit II

Catalog #

17898RF

Lot #

All

Language

English

Document Type

Product Information Sheet

Product Name

EasySep™ Human CD45 Depletion Kit II

Catalog #

17898

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

RoboSep™ Human CD45 Depletion Kit II

Catalog #

17898RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

RoboSep™ Human CD45 Depletion Kit II

Catalog #

17898RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

RoboSep™ Human CD45 Depletion Kit II

Catalog #

17898RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human CD45 Depletion Kit II

Catalog #

17898

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human CD45 Depletion Kit II

Catalog #

17898

Lot #

All

Language

English

相关材料与文献

Classification of T-cell activation via autofluorescence lifetime imaging. A. J. Walsh et al. Nature biomedical engineering 2020 jul

Abstract

The function of a T cell depends on its subtype and activation state. Here,we show that imaging of the autofluorescence lifetime signals of quiescent and activated T cells can be used to classify the cells. T cells isolated from human peripheral blood and activated in culture using tetrameric antibodies against the surface ligands CD2,CD3 and CD28 showed specific activation-state-dependent patterns of autofluorescence lifetime. Logistic regression models and random forest models classified T cells according to activation state with 97-99{\%} accuracy,and according to activation state (quiescent or activated) and subtype (CD3+CD8+ or CD3+CD4+) with 97{\%} accuracy. Autofluorescence lifetime imaging can be used to non-destructively determine T-cell function.

View publication

Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome. Y. Chen et al. Blood advances 2020 oct

Abstract

Murine models of myeloid neoplasia show how leukemia infiltration alters the hematopoietic stem cell (HSC) niche to reinforce malignancy at the expense of healthy hematopoiesis. However,little is known about the bone marrow architecture in humans and its impact on clinical outcome. Here,we dissect the bone marrow niche in patients with acute myeloid leukemia (AML) at first diagnosis. We combined immunohistochemical stainings with global gene expression analyses from these AML patients and correlated them with clinical features. Mesenchymal stem and progenitor cells (MSPCs) lost quiescence and significantly expanded in the bone marrow of AML patients. Strikingly,their HSC- and niche-regulating capacities were impaired with significant inhibition of osteogenesis and bone formation in a cell contact-dependent manner through inhibition of cytoplasmic $\beta$-catenin. Assessment of bone metabolism by quantifying peripheral blood osteocalcin levels revealed 30{\%} lower expression in AML patients at first diagnosis than in non-leukemic donors. Furthermore,patients with osteocalcin levels ≤11 ng/mL showed inferior overall survival with a 1-year survival rate of 38.7{\%} whereas patients with higher osteocalcin levels reached a survival rate of 66.8{\%}. These novel insights into the human AML bone marrow microenvironment help translate findings from preclinical models and detect new targets which might pave the way for niche-targeted therapies in AML patients.

View publication

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. M. Seyfrid et al. Journal for immunotherapy of cancer 2022 jan

Abstract

PURPOSE Glioblastoma (GBM) patients suffer from a dismal prognosis,with standard of care therapy inevitably leading to therapy-resistant recurrent tumors. The presence of cancer stem cells (CSCs) drives the extensive heterogeneity seen in GBM,prompting the need for novel therapies specifically targeting this subset of tumor-driving cells. Here,we identify CD70 as a potential therapeutic target for recurrent GBM CSCs. EXPERIMENTAL DESIGN In the current study,we identified the relevance and functional influence of CD70 on primary and recurrent GBM cells,and further define its function using established stem cell assays. We use CD70 knockdown studies,subsequent RNAseq pathway analysis,and in vivo xenotransplantation to validate CD70's role in GBM. Next,we developed and tested an anti-CD70 chimeric antigen receptor (CAR)-T therapy,which we validated in vitro and in vivo using our established preclinical model of human GBM. Lastly,we explored the importance of CD70 in the tumor immune microenvironment (TIME) by assessing the presence of its receptor,CD27,in immune infiltrates derived from freshly resected GBM tumor samples. RESULTS CD70 expression is elevated in recurrent GBM and CD70 knockdown reduces tumorigenicity in vitro and in vivo. CD70 CAR-T therapy significantly improves prognosis in vivo. We also found CD27 to be present on the cell surface of multiple relevant GBM TIME cell populations,notably putative M1 macrophages and CD4 T cells. CONCLUSION CD70 plays a key role in recurrent GBM cell aggressiveness and maintenance. Immunotherapeutic targeting of CD70 significantly improves survival in animal models and the CD70/CD27 axis may be a viable polytherapeutic avenue to co-target both GBM and its TIME.

View publication

View All Publications